Starting August 1, Australia's Pharmaceutical Benefits Scheme will provide cheaper Trikafta access for 2-5 year-olds with cystic fibrosis, benefiting around 330 kids annually.
Starting August 1, the Australian government will provide cheaper treatment for toddlers and preschoolers with cystic fibrosis via the Pharmaceutical Benefits Scheme. Trikafta, a medicine costing around $250,000 without subsidies, will now be accessible to children aged 2-5, benefiting approximately 330 kids annually. The price will be capped at $31.60 or $7.70 for concession cardholders, improving access to life-changing treatment for these young patients.
July 28, 2024
8 Articles